Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
TAFINLAR + MEKINIST Drug Insight and Market Forecast − 2032
... major markets. A detailed picture of the TAFINLAR + MEKINIST for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period ... Read More
-
DCVax-L Emerging Drug Insight and Market Forecast − 2032
... picture of the DCVax-L for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More
-
GYM-329 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the GYM-329 for FSHD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
AKL4 Emerging Drug Insight and Market Forecast − 2032
... the AKL4 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
Sprifermin Emerging Drug Insight and Market Forecast − 2032
... the sprifermin for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
GABLOFEN Drug Insight and Market Forecast − 2032
... for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a ... Read More
-
JAKAFI Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the JAKAFI for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is ... Read More
-
MPH966 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the MPH966 for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is ... Read More
-
AV-GBM-1 Emerging Drug Insight and Market Forecast − 2032
... picture of the AV-GBM-1 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More
-
Esophageal Squamous Cell Carcinoma Market Research Report Forecast till 2030
... research exercises and item endorsements, and rising public mindfulness are driving market development. The rising commonness of achalasia help market development because achalasia patients have a higher gamble of Esophageal Squamous Cell Carcinoma than everybody. ... Read More
-
TCR-Therapy - Pipeline Insight, 2023
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage TCR-Therapy Understanding ... Read More
-
HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032
... and drug resistance mechanisms. In 2022, the United States accounted for the maximum share of the total market of HER2-positive breast cancer in the 7MM was around 60%. The approval of HERCEPTIN marked a turning ... Read More
-
RTX-GRT7039 Emerging Drug Insight and Market Forecast − 2032
... the RTX-GRT7039 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
AVASTIN Drug Insight and Market Forecast − 2032
... the AVASTIN for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along ... Read More
-
ZULRESSO Drug Insight and Market Forecast − 2032
... ZULRESSO for PPD in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the ZULRESSO for PPD. The report provides insights about mechanism of ... Read More
-
LAM561 Emerging Drug Insight and Market Forecast − 2032
... picture of the LAM561 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More
-
Losmapimod Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the losmapimod for FSHD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
JOYCLU Drug Insight and Market Forecast − 2032
... for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in this report ... Read More
-
XP-3924 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the XP-3924 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More
-
IMCY-0098 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the IMCY-0098 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More
-
Hypoparathyroidism - Market Insight, Epidemiology And Market Forecast - 2032
... hormone (PTH) in the circulation. The most common cause of hypoparathyroidism is the removal of all four parathyroid glands or postoperative complications of thyroidectomy, leading to insufficient PTH levels in the body. Nonsurgical causes of ... Read More
-
Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032
... be psychologically devastating. Alopecia areata is clinically heterogeneous, and the course of the disease is unpredictable, with spontaneous regrowth of hair occurring in 80% of patients within the first year and sudden relapse at any ... Read More
-
Blockchain in Drug Discovery and Clinical Trials Market, 2023-2035
... drugs and other pharmaceutical products, thereby reducing the prevalence of counterfeit drugs and medicine. The drug discovery process, which involves the identification of a relevant biological target and a corresponding pharmacological lead, is deemed crucial ... Read More
-
Retinopathy of Prematurity - Market Insight, Epidemiology And Market Forecast - 2032
... most important risk factor for developing Retinopathy of Prematurity is the baby’s age and weight at birth. Especially children with gestational age at birth below 31 weeks or a birth weight of less than 1,500 ... Read More
-
Dupilumab Emerging Drug Insight and Market Forecast − 2032
... of the dupilumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this ... Read More
Research Assistance
